The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Financial and time toxicity with CAR-T and bispecifics in R/R lymphoma and myeloma
Swetha Thiruvengadam, MD, City of Hope, Duarte, CA, discusses the preliminary results of a prospective cohort study examining financial toxicity and time toxicity in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) treated with CAR T-cell therapy or bispecific antibodies. The study’s mixed methods approach revealed high rates of financial and time toxicity and additionally aims to assess the impact on time spent interacting with the healthcare system and quality of life. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This ASH I presented some initial results of our pilot prospective cohort study evaluating financial toxicity and time toxicity in patients with relapse refractory non-Hodgkin lymphoma and multiple myeloma who have received either bispecifics or CAR T-cell therapy in a standard of care setting. As we all know, the advent of these therapies has really transformed the treatment landscape, but are associated with high costs and financial toxicity as well as time toxicity...
This ASH I presented some initial results of our pilot prospective cohort study evaluating financial toxicity and time toxicity in patients with relapse refractory non-Hodgkin lymphoma and multiple myeloma who have received either bispecifics or CAR T-cell therapy in a standard of care setting. As we all know, the advent of these therapies has really transformed the treatment landscape, but are associated with high costs and financial toxicity as well as time toxicity. In our study, so far, we’ve enrolled 66 patients in this interim analysis, and we have found about a quarter of patients have experienced financial toxicity. The study consists of a mixed methods analysis where prospective surveys were administered for patients at the baseline, one week, one month, three months, and six months, both to assess financial toxicity, time in contact with the healthcare system, as well as other quality of life measures. Qualitative analysis is also being conducted with focused one-on-one interviews with some patients and caregivers. So I think our results indicate high rates of financial and time toxicity with both patients receiving CAR T-cell therapy and bispecific antibodies in these disease patient populations with relapsed refractory myeloma and non-Hodgkin lymphoma. We’re enrolling more patients and a larger sample size will be needed to better understand differences between bispecific versus CAR T with respect to financial and time toxicity.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
